Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were moving sharply higher Friday morning, rising 1.2% to 2,061.9 on the S&P Asia 50 ADR Index. With the gain, the index is poised to
BeiGene (NASDAQ:BGNE) Shareholders Have Endured a 55% Loss From Investing in the Stock Three Years Ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term BeiGene, Ltd. (NASDAQ:BGNE) shareholders know that all too well, since the share price is
When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
Late night surge! The renminbi and A50 rose, and China concept stocks rose across the board, while gold and silver soared.
Tonight, the U.S. June CPI data was released, showing that inflation in the United States has cooled across the board.
Bank of America Securities downgrades Beigene (06160.HK) target price to HKD 92.09, rating 'neutral'.
Bank of America Securities research report pointed out that Beigene's (06160.HK) independently developed BTK inhibitors zanubrutinib, orelabrutinib, ibrutinib, and acalabrutinib recorded sales of RMB 60.9 million, 26.8 million, 25.3 million, and 0.3 million yuan respectively in May, accounting for 53.7%, 23.7%, 22.3%, and 0.3% of the overall sales in the mainland market. The bank lowered its 2024 forecast due to the updated sales data and intensified competition in the mainland BTK inhibitor market.
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A Securities
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A
BeiGene Is Maintained at Neutral by B of A Securities
BeiGene Is Maintained at Neutral by B of A
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $152.5.
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 5.92% B of A Securities $180 → $152.5 Maintains Neutral 05/09/2024 76.43% TD Cowen $236 → $254
Express News | Beigene : BofA Global Research Cuts Price Objective to $152.5 From $180
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Cuts Target Price to $152.5
BofA Securities analyst David Li maintains $BeiGene(BGNE.US)$ with a hold rating, and adjusts the target price from $180 to $152.5.According to TipRanks data, the analyst has a success rate of 16.2%
BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Soochow Securities: "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain" Approved, and the innovative drugs sector is expected to strengthen.
Soochow Securities released research reports stating that the specific provisions of the "Implementation Plan for Full-chain Support of Innovative Drug Development" are expected to be implemented soon. In addition, the innovative drug sector is currently at a historically relatively low level. In the second half of the year, there will be multiple catalysts such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the innovative drug sector going global, which may lead to a strong performance in the innovative drug sector.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Express News | The State Council has approved the "Implementation Plan for Supporting the Development of Innovative Drugs across the Whole Value Chain".
Beigene (06160) issued a total of 0.7363 million shares due to restricted stock units being granted.
Beigene (06160) announced that on June 30, 2024, due to restricted shares granted under the equity plan...
Midday Snapshot | The gains of the three major Hang Seng indexes narrowed, auto stocks were strong, and NIO Inc stock rose over 6%.
Golden industrial concept leads the gains, with Lingbao Gold up over 6%, Zijin Mining Group and SD Gold up over 4%, Zhaojin Mining and Chi Silver GP up over 3%.
BeiGene Ltd Announces New Stock Grants
Beigene (06160.HK): Granted a total of 1760 American depositary share warrants and 56,600 restricted share units of American depositary shares.
Beigene (06160.HK) announced on July 3, that on June 28, 2024, the board of directors' compensation committee granted options to purchase a total of 1,760 American depositary shares and restricted stock units involving a total of 56,609 American depositary shares to 112 grantees in accordance with the terms of the 2016 equity incentive plan.